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ABSTRACT
Congenital cytomegalovirus infection causes lethal diseases with neurological, visual, 
auditory and systemic injuries, including the hemophagocytic syndrome. Hemophagocytic 
lymphohistiocytosis (HLH) can be caused by primary hereditary immunological defects, 
as well as several infectious triggering factors, such as viruses, bacteria and fungus, among 
them the cytomegalovirus (CMV). Here we present the case report of a male newborn male, 
delivered by cesarean at term (gestation age of 39 weeks), weighing 3,250 g, with suffusion 
skin lesions spread throughout the body, anemia, generalized edema, hepatosplenomegaly, 
thrombocytopenia associated with grunts and difficulty breathing, treated with ganciclovir 
after receiving the diagnosis of congenital CMV infection. After a few days of hospitalization, 
the patient presented with high fever, persistent hepatosplenomegaly and pancytopenia, 
in addition to elevated ferritin and triglycerides, receiving the diagnosis of HLH treated 
with immunosuppressive therapy, corticosteroids and intravenous human immunoglobulin. 
The present case report highlights the importance for health professionals to carry out the 
investigation of congenital diseases, especially in developing countries, as well as their 
complications, such as HLH.
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INTRODUCTION
Cytomegalovirus (CMV) is a virus of the herpesviridae family that is responsible 
for the most common and widespread congenital infections worldwide1. Congenital 
CMV is a global epidemic, and the prevalence of congenital CMV in Brazil is around 
0.5-1.1%1. CMV can cause primary infection, primary and persistent infection, 
reinfection by a different strain or recurrence of the already established infection1.
Although the majority of the newborns with CMV infection show no signs of 
the disease at birth or later, approximately 10-15% of congenital CMV patients will 
present symptoms at birth2.
Cases of congenital CMV infection present with several signs and symptoms, 
including petechiae, splenomegaly, hepatomegaly, thrombocytopenia, hepatitis, 
intrauterine growth restriction that after birth will be perceived as a small for 
gestational age newborn, central nervous system involvement such as microcephaly, 
intracranial calcifications, ocular alterations such as chorioretinitis, and sensorineural 
hearing loss2. However, the literature does not describe HLH associated with 
intrauterine CMV infection in the neonatal period and the therapeutic protocols 
for such cases.
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CASE REPORT
A male newborn was delivered by cesarean section 
at full-term (39 weeks), weighting 3,250 g and an Apgar 
score of 8/10 (1st and 5th minute of life, respectively) in 
the city of Sao Joao Batista, Maranhao State, Northeast 
Brazil. The newborn was admitted to a children’s hospital 
presenting with petechiae and skin suffusions lesions spread 
throughout the body since birth and associated with grunts 
and respiratory distress. The mother did not attend pre-natal 
care. The initial physical examination performed 12 h after 
birth revealed the presence of pallor, widespread petechial 
skin lesions, a scaly palmoplantar rash (Figure 1) and the 
presence of hepatosplenomegaly in the first hours of life. 
The newborn was severely ill, had generalized edema but no 
jaundice. The maternal and neonatal blood groups were not 
incompatible. Additionally, there was marked microcephaly 
with a cephalic perimeter of 30.5 cm for a gestational age 
of 39 weeks and a birth weight of 3,250 g. 
On the 1st day of life, he was admitted to the intensive care 
unit, with respiratory distress and arterial blood gases showing 
a moderate metabolic acidosis. The newborn was intubated 
and placed on mechanical ventilation. A complete blood 
count was performed which indicated anemia with 6.5 g/dL 
of hemoglobin, leukocytosis (WBC count of 38,900/mm³), 
presence of atypical lymphocytes and thrombocytopenia 
(45,000/mm³). The chest X-ray was normal.
On the 3rd day of life, serological results showed 
the presence of IgM and IgG antibodies anti-CMV and 
treatment with ganciclovir (12 mg/kg/day) was started. A 
transthoracic echocardiogram was performed, revealing a 
normal result. Serology was negative for HIV and other 
TORCH infections, i.e., toxoplasmosis, rubella, zika, herpes 
simplex, and other organisms including syphilis, parvovirus 
and varicella zoster.
On the 5th day of life, a computed tomography of the 
skull showed multiple parenchymal calcifications located in 
the periventricular region and lentiform nucleus (Figure 1). 
The retinal scan was normal. There were no cytological or 
biochemical alterations in the cerebrospinal fluid exam, 
and the Polymerase Chain Reaction (PCR) for CMV was 
negative.
On the 7th day of life, the urinary PCR for CMV was 
positive and the serum quantitative PCR for CMV detected 
1.2 million copies per mL (normal range <100 copies/mL). 
On the 17th day of life and after 14 days of treatment 
with ganciclovir and having received one blood 
transfusion, the clinical and laboratory results worsened 
and hepatosplenomegaly, pancytopenia and dysthermia 
were still observed. The newborn underwent a laboratory 
screening for the haemophagocytic lymphohistiocytosis 
(HLH) syndrome that revealed the persistence of anemia 
(hemoglobin 7.4 g/dL), hematocrit 21.9%, and the presence 
of leukopenia (leukocytes 3,240/mm3) with neutropenia 
(1,340/mm3), atypical lymphocytes and persistence of 
thrombocytopenia (21,000/mm3). The serum ferritin was 
extremely high 1,076.80 ng/mL and elevated triglycerides 
370 mg/dL. A bone marrow aspiration was performed, 
showing a hypocellular and hemodiluted bone marrow, 
without hemophagocytosis. At that time, the newborn was 
on assisted ventilatory support, receiving hourly blood 
transfusions.
Figure 1 - Initial clinical observation of the newborn (A) Non-contrast computed tomography of the skull shows the presence of 
calcifications caused by congenital cytomegalovirus infection in a newborn (three weeks old). (B) Characteristic lesions of congenital 
cytomegalovirus infection in a 12-hours newborn. (C) Infant after seven months of follow-up showing a satisfactory improvement.
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Thus, the newborn fulfilled five criteria for the diagnosis 
of HLH, two clinical criteria (dysthermia and splenomegaly) 
and three laboratory criteria (pancytopenia, increased 
ferritin and increased triglycerides). On the 20th day of life, 
he was treated with human intravenous immunoglobulin 
at a dose of 500 mg/kg/day for five days and also with 
corticosteroid therapy (dexamethasone at a dose of 10 mg/m2 
daily for two weeks, followed by 5 mg/m2 for two weeks, 
2.5 mg/m2 for two weeks and finally 1.25 mg/m2 for two 
more weeks).
After 10 days of treatment with human intravenous 
immunoglobulin and corticosteroid, the newborn showed 
a gradual clinical and laboratory improvement. He was 
extubated and presented a reduction in serum ferritin level 
to 338 ng/mL and triglycerides to 199 mg/dL, a progressive 
improvement in the leukogram (leukocytosis 8,136/mm3, 
7.7 g/dL hemoglobin, and platelets 224,500/mm3), and a 
proportional regression of the hepatosplenomegaly with 
complete remission of the splenomegaly two months after 
the beginning of the treatment. The subsequent treatment 
was maintained with dexamethasone for eight weeks. The 
patient showed clinical and laboratory improvement and was 
discharged from the hospital for the outpatient follow-up. 
The child underwent a 6-month follow-up testing at the 
outpatient clinic for a genetic screening with the collection 
of cells from the inner region of the infant’s mouth to 
perform DNA extraction. Then, a number of genetic 
mutations were investigated (PRF1, STX11, STXBP2 
and UNC13D), all of which were negative. Because the 
microcephaly was pre-existent since the intrauterine period, 
the patient was referred for neuro-psychomotor stimulation 
and specialized follow-up. Seven months after the diagnosis 
(Figure 1), the patient still had mild microcephaly and a 
mild delay in the neuro-psychomotor development, but no 
visual or auditory losses.
DISCUSSION
The municipality of Sao Joao Batista has a population 
of 20,665 inhabitants and is located in the central region of 
Maranhao State, Northeast Brazil. Since serology for CMV 
is not part of the prenatal screening and, in addition, it is 
not a compulsorily notifiable disease, there are no official 
incidence or prevalence estimates. 
Our case presented a complication that has not yet 
been described in the literature in the neonatal period, i.e., 
the association of HLH with congenital CMV infection. 
The patient exhibited a favorable clinical response to the 
antiviral ganciclovir, aside from the corticosteroid and the 
intravenous human immunoglobulin therapy. 
Unlike the case report described by Silwedel et al.3, of a 
late premature newborn with a birth weight of 1,840 g and 
a rare case of secondary HLH triggered by a symptomatic 
infection (CMV) acquired postnatally, probably transmitted 
through breast milk, the newborn was treated with 
ganciclovir without the need of immunosuppressive 
therapy, while in our case report, the HLH was secondary 
to intrauterine cytomegalovirus infection, in addition to the 
successful treatment with intravenous immunoglobulin, 
corticosteroid and ganciclovir.
The newborn in our case was initially clinically 
and serologically diagnosed with congenital CMV 
infection, urinary and serum PCR for CMV, consistent 
with persistence of an acute CMV infection, treated with 
ganciclovir. Ganciclovir is the antiviral drug of choice for 
severe CMV disease4.
The urine sample required for the PCR to detect CMV-
DNA can be collected non-invasively and the viral load in 
urine can be quantified with this fast, reliable, and specific 
method5,6. In this case, the patient underwent urinary PCR 
for CMV before starting the treatment with ganciclovir.
After two weeks of antiviral treatment with 
unsatisfactory clinical response, the newborns’s condition 
worsened with the appearance of dysthermia, no change 
in hepatosplenomegaly, pancytopenia, and the detection 
of increased ferritin and triglycerides. These findings 
fulfilled the criteria of HLH, with the presence of two 
clinical criteria (dysthermia and splenomegaly) and three 
laboratory criteria (pancytopenia, hyperferritinemia and 
hypertriglyceridemia), according to the international 
criteria for hemophagocytic lymphohistiocytosis-2004. 
Furthermore, this is in line with the study by Balwierz et 
al.7 that reported that HLH can occur in all age groups. 
Depending on the etiology, HLH can be divided into 
genetic (primary) and acquired (secondary) forms8. The 
primary cause of HLH has been ruled out, as the genetic 
tests to detect PRF1, STX11, STXBP2 and UNC13D gene 
mutations were negative. In this case, HPS was reported 
as being secondary to a viral infection that has tropism 
for hematopoietic bone marrow cells9. The evaluation of 
other factors that predispose to HLH, such as the direct 
antiglobulin test and the investigation of neonatal lupus 
syndrome were unfortunately not performed in this case.
Hyperferritinemia plays an important role as a marker of 
disease activity to evaluate therapy response and prognosis. 
In this case, there was a gradual decrease in the ferritin level 
after 10 days of treatment9. HLH can occur due to genetic 
causes and secondary causes leading to systemic diseases, 
while Epstein-Barr virus infection is the main cause in 
children10. Increased ferritin levels and pancytopenia are the 
most important laboratory abnormalities observed in HLH10. 
The literature highlights that the anatomopathological 
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criterion of HLH may be useful, but is not enough to 
diagnose the syndrome10.
The decision to start therapy for HLH was indicated by 
the presence of five clinical and laboratory criteria that defined 
HLH, even without the presence of the bone marrow aspirate 
criterion. In this case, the newborn was subjected to treatment 
with intravenous human immunoglobulin and corticosteroids. 
In the treatment protocol of the second international study of 
haemophagocytic lymphohistiocytosis proposed in 1994, and 
revised in 2004 by the Histiocyte Society, for the treatment 
of primary and secondary HLH forms, they recommended 
the intravenous human immunoglobulin as a therapeutic 
alternative. However, in more recent reports such as Chesshyre 
et al.11, the authors described the therapeutic role of intravenous 
human immunoglobulin and corticotherapy, as therapeutic 
options of choice for the treatment of secondary HLH, as well 
as the role of Anakinra, a recombinant and slightly modified 
version of the human interleukin 1 receptor antagonist protein.
HLH is an excessive and prolonged response to 
antigen-presenting cells, in this case macrophages and 
histiocytes, which promote a systemic and potentially 
lethal inflammatory process. Early diagnosis and immediate 
treatment is essential to reduce mortality12. In this case, 
the symptoms continued or worsened with the presence 
of other disease markers. Drug therapy can reduce an 
exacerbated response, and this patient was treated with 
human intravenous immunoglobulin (gamma globulin) and 
dexamethasone, which were fundamental for the infant’s 
clinical and laboratory improvement. 
The patient improved satisfactorily with a favorable 
clinical and laboratory response, reverting the phagocytic 
activation. Despite the systemic improvement, the 
microcephaly progressed, however with no hearing loss so 
far, with a slight delay in the neuro-psychomotor development 
and monthly follow-ups with a multidisciplinary and a 
medical team. 
CONCLUSION 
Symptomatic congenital CMV infection is a life 
threatening disease that can progress with neurological and 
hearing loss and delayed neuro-psychomotor development. 
However, the description of an HLH case in the neonatal 
period with a satisfactory clinical response is unprecedented 
in the literature. This medical condition, although rare, 
should be considered in all cases of newborns with 
symptomatic congenital infection.
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